Read More

Milestone Pharmaceuticals Announced Saturday: Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Showed Statistically Significant Reduction In Ventricular Rate By 30 Beats Per Minute For Episodes Of Atrial Fibrillation With Rapid Ventricular Ra…

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in

MIST